Profile data is unavailable for this security.
About the company
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
- Revenue in USD (TTM)0.00
- Net income in USD-509.63m
- Incorporated2013
- Employees414.00
- LocationVaxcyte Inc825 INDUSTRIAL ROAD, STE. 300SAN CARLOS 94070United StatesUSA
- Phone+1 (650) 837-0111
- Fax+1 (302) 655-5049
- Websitehttps://vaxcyte.com/